Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAB7A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAB7A Recombinant Protein (WT & CMT2B-associated Mutants) High purity (>95% by SDS-PAGE), Endotoxin Controlled, Sequence Verified. Suitable for GTPase activity and nucleotide exchange assays. |
View RAB7A Products |
| Gene Delivery | RAB7A Promise-ORF / Lentivirus Full-length ORF in lentiviral vectors for stable cell line construction to monitor endosome-to-lysosome trafficking. |
View RAB7A Products |
| Benchmark Ab | Anti-RAB7A Recombinant Antibody High-specificity positive control for Western Blot, Immunofluorescence, and immunoprecipitation assays. |
View RAB7A Products |
| Validator | RAB7A siRNA Set Target-specific siRNA pool for gene knockdown validation in functional and phenotypic assays. |
View RAB7A Products |
| Related Target A | EGFR RAB7A regulates the endosomal degradation of EGFR; key pathway partner in oncology resistance studies. |
View EGFR Products |
| Related Target B | LAMP1 Lysosomal marker used in co-localization assays with RAB7A to verify lysosome fusion and cargo delivery. |
View LAMP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GTP/GDP State Differentiation | Sequence-verified WT and mutant proteins with high conformational stability for nucleotide-loading screening. |
| Intracellular Localization Imaging | High-titer Lentiviral particles expressing fluorescently tagged RAB7A for real-time live-cell trafficking assays. |
| Lack of Controls | Validated recombinant antibodies with high signal-to-noise ratio for endogenous detection. |
| False Positives | Sequence-specific siRNA pools included to confirm target-specific phenotypic knockdown. |
Live RAB7A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RAB7A therapeutics is intensifying, with major players shifting focus from traditional targets to intracellular trafficking modulators. As first-generation therapies targeting endolysosomal pathways reach the clinic, the next wave of R&D is targeting RAB7A's critical role in EGFR/HER2 degradation bypass, autophagosome-lysosome fusion in neurodegeneration (such as CMT2B), and viral entry mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Oncology (EGFR-driven cancers), CMT2B Neuropathy | Biochemical GTPase activity assay (Requires high-purity WT/Mutant recombinant proteins) |
| Gene Therapy / ASO | Neurology-focused Biopharma | Charcot-Marie-Tooth Disease Type 2B (CMT2B) | Expression validation (Requires stable cell line construction via Lentivirus) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Pioneers | Solid Tumors, Drug-Resistant Cancers | In vitro degradation kinetics (Requires siRNA validation and high-specificity antibodies) |